Drugs that mimic glucagonlike peptide-1 (GLP-1), such as semaglutide—marketed as Ozempic or Wegovy—have revolutionized the treatment of obesity and type 2 diabetes, but they have major drawbacks. “[They] are expensive to manufacture, they have to be refrigerated, and they often have to be injected because they cannot go through the gastrointestinal tract without being degraded,” explains Alejandra Tomas, a cell biologist at Imperial College London who studies the cellular receptor GLP-1 drugs target. That’s all because they consist of peptides, or long chains of amino acids.

SEATTLE – April 15, 2025 – Opanga, a global leader in AI-powered network optimization solutions, today announced it has received strategic investments from Boulder Ventures, Cisco Investments, the global corporate venture investment arm of Cisco, Grayhawk Capital and Trilogy Equity Partners.

This financing will support future product development, sales and marketing for Opanga’s AI-driven platform, RAIN, as the company continues expanding its deployments with global telecom operators to enhance network optimization and improve real-time customer experience across the telecom industry.

With the US imposing harsh protectionist measures via aggressive import taxes, American and global manufacturers are racing to find solutions and responses. Margins are under siege. Strategic sourcing is being rewritten in real time.

Here’s the hard truth: if you’re waiting for your supply chain team or ERP vendor to sort this out, you’re already behind.

This is not just a compliance problem. It’s a C-Suite problem. And it demands a C-Suite solution.

Today Black Bear Energy Inc. turns ten! We are humbled to represent over 100 of the most forward-thinking real estate owners, honored to work with many leading partners and privileged to be a part of this industry.

My biggest learning over this past decade; the importance of culture to the success of an organization. Thank you to everyone who has helped shape this company and continues to do so.

We love what we do and we are just getting started.  ONWARD!!

RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). Both trials successfully achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.